Home Alzheimer’s Disease Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer

Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer

The phase III KEYNOTE-177 trial designed to evaluate first-line pembrolizumab (Keytruda) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic advanced colorectal cancer met 1 of its dual primary endpoints of progression-free survival (PFS), according to Merck, the agent’s developer.

Based on an interim analysis conducted by an independent data monitoring committee (DMC), pembrolizumab monotherapy was found to demonstrate a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy. 

The company indicated that they will be presenting data from this study at an upcoming medical congress. 

“These head-to-head data with Keytruda are the first time a single-agent, anti-cancer therapy, and particularly an anti-PD-1 monotherapy, achieved a statistically significant improvement in…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments